Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Street Poller Media and The Boom of the Street Interview Ad Industry 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Add as a preferred source on Google
CANTON, Mass., April 04, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
